Compare DSU & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSU | PHAT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.4M | 590.6M |
| IPO Year | 1998 | 2019 |
| Metric | DSU | PHAT |
|---|---|---|
| Price | $8.63 | $5.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.05 |
| AVG Volume (30 Days) | 396.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $79.63 |
| Revenue Next Year | N/A | $54.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $8.42 | $5.02 |
| 52 Week High | $10.40 | $18.31 |
| Indicator | DSU | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 34.30 |
| Support Level | $8.42 | $5.02 |
| Resistance Level | $9.94 | $7.72 |
| Average True Range (ATR) | 0.08 | 0.62 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 65.22 | 28.10 |
Blackrock Debt Strategies Fund Inc is a closed-end management investment company. Its primary investment objective is to seek to provide current income by investing in a diversified portfolio of U.S. companies debt instruments, including senior and subordinated corporate loans, both secured and unsecured, which are rated in the lower rating categories of the established rating services or unrated debt instruments, which are in the judgment of the investment adviser of equivalent quality. The Fund may invest directly in debt instruments or synthetically through the use of derivatives. The Fund's secondary investment objective is to seek to provide capital appreciation.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.